Does the media prefer HHH or TSHA?

In the previous week, Taysha Gene Therapies had 13 more articles in the media than Howard Hughes. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 2 mentions for Howard Hughes. Howard Hughes' average media sentiment score of 1.00 beat Taysha Gene Therapies' score of 0.44 indicating that Howard Hughes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Howard Hughes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TSHA or PTGX?

In the previous week, Taysha Gene Therapies had 7 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 8 mentions for Protagonist Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.44 beat Protagonist Therapeutics' score of 0.25 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMVT or TSHA more profitable?

Taysha Gene Therapies' return on equity of -56.07% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Taysha Gene Therapies N/A -56.07% -40.16%

Does the media favor IMVT or TSHA?

In the previous week, Taysha Gene Therapies had 2 more articles in the media than Immunovant. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 13 mentions for Immunovant. Taysha Gene Therapies' average media sentiment score of 0.44 beat Immunovant's score of -0.75 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Taysha Gene Therapies 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TSHA or RYTM?

In the previous week, Taysha Gene Therapies had 8 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 7 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.71 beat Taysha Gene Therapies' score of 0.44 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LNTH or TSHA?

In the previous week, Taysha Gene Therapies had 4 more articles in the media than Lantheus. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 11 mentions for Lantheus. Taysha Gene Therapies' average media sentiment score of 0.44 beat Lantheus' score of -0.03 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Taysha Gene Therapies 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Taysha Gene Therapies (TSHA) Competitors

$6.34 +0.13 (+2.09%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$6.28 -0.06 (-0.95%)

As of 06/26/2026 07:59 PM Eastern

Compare

TSHA vs. HHH, PTGX, IMVT, RYTM, and LNTH

Should you buy Taysha Gene Therapies stock or one of its competitors? MarketBeat compares Taysha Gene Therapies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Taysha Gene Therapies include Howard Hughes (HHH), Protagonist Therapeutics (PTGX), Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), and Lantheus (LNTH).

How does Taysha Gene Therapies compare to Howard Hughes?

Howard Hughes (NYSE:HHH) and Taysha Gene Therapies (NASDAQ:TSHA) are related companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Howard Hughes presently has a consensus price target of $85.00, suggesting a potential upside of 17.62%. Taysha Gene Therapies has a consensus price target of $12.38, suggesting a potential upside of 95.34%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Howard Hughes	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Howard Hughes has a net margin of 8.04% compared to Taysha Gene Therapies' net margin of 0.00%. Howard Hughes' return on equity of 5.41% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Howard Hughes	8.04%	5.41%	1.61%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Howard Hughes	$1.47B	2.92	$131.88M	$2.04	35.42
Taysha Gene Therapies	$9.77M	186.48	-$109M	-$0.38	N/A

93.8% of Howard Hughes shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 48.0% of Howard Hughes shares are held by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Howard Hughes has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

In the previous week, Taysha Gene Therapies had 13 more articles in the media than Howard Hughes. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 2 mentions for Howard Hughes. Howard Hughes' average media sentiment score of 1.00 beat Taysha Gene Therapies' score of 0.44 indicating that Howard Hughes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Howard Hughes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Howard Hughes beats Taysha Gene Therapies on 10 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Protagonist Therapeutics?

Taysha Gene Therapies (NASDAQ:TSHA) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Taysha Gene Therapies has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Taysha Gene Therapies has higher earnings, but lower revenue than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	186.48	-$109M	-$0.38	N/A
Protagonist Therapeutics	$46.02M	170.32	-$130.15M	-$1.81	N/A

Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market.

Taysha Gene Therapies presently has a consensus target price of $12.38, indicating a potential upside of 95.34%. Protagonist Therapeutics has a consensus target price of $115.21, indicating a potential downside of 5.47%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Taysha Gene Therapies had 7 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 8 mentions for Protagonist Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.44 beat Protagonist Therapeutics' score of 0.25 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Taysha Gene Therapies beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Immunovant currently has a consensus price target of $37.33, indicating a potential downside of 3.90%. Taysha Gene Therapies has a consensus price target of $12.38, indicating a potential upside of 95.34%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

47.1% of Immunovant shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Taysha Gene Therapies had 2 more articles in the media than Immunovant. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 13 mentions for Immunovant. Taysha Gene Therapies' average media sentiment score of 0.44 beat Immunovant's score of -0.75 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Taysha Gene Therapies	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Taysha Gene Therapies has higher revenue and earnings than Immunovant. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Taysha Gene Therapies	$9.77M	186.48	-$109M	-$0.38	N/A

Taysha Gene Therapies' return on equity of -56.07% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Summary

Taysha Gene Therapies beats Immunovant on 14 of the 15 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Rhythm Pharmaceuticals?

Taysha Gene Therapies (NASDAQ:TSHA) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Taysha Gene Therapies has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Taysha Gene Therapies' return on equity of -56.07% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Taysha Gene Therapies presently has a consensus target price of $12.38, indicating a potential upside of 95.34%. Rhythm Pharmaceuticals has a consensus target price of $133.13, indicating a potential upside of 21.20%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Taysha Gene Therapies is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

77.7% of Taysha Gene Therapies shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Taysha Gene Therapies has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	186.48	-$109M	-$0.38	N/A
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A

In the previous week, Taysha Gene Therapies had 8 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 7 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.71 beat Taysha Gene Therapies' score of 0.44 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

Summary

Taysha Gene Therapies beats Rhythm Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Lantheus has a net margin of 18.05% compared to Taysha Gene Therapies' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Lantheus presently has a consensus target price of $101.86, suggesting a potential downside of 7.23%. Taysha Gene Therapies has a consensus target price of $12.38, suggesting a potential upside of 95.34%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

99.1% of Lantheus shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Lantheus has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.64	$233.56M	$4.15	26.46
Taysha Gene Therapies	$9.77M	186.48	-$109M	-$0.38	N/A

In the previous week, Taysha Gene Therapies had 4 more articles in the media than Lantheus. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 11 mentions for Lantheus. Taysha Gene Therapies' average media sentiment score of 0.44 beat Lantheus' score of -0.03 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Taysha Gene Therapies	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Taysha Gene Therapies beats Lantheus on 9 of the 17 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSHA vs. The Competition

Export

Metric	Taysha Gene Therapies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.82B	$6.01B	$7.04B	$12.18B
Dividend Yield	N/A	0.63%	2.66%	6.24%
P/E Ratio	-16.68	9.23	26.13	24.17
Price / Sales	186.48	23.86	600.49	118.58
Price / Cash	N/A	8.98	47.95	55.62
Price / Book	7.04	4.33	10.78	6.36
Net Income	-$109M	$99.67M	$3.58B	$337.99M
7 Day Performance	-1.25%	7.76%	2.22%	0.10%
1 Month Performance	7.09%	4.03%	-0.09%	-1.28%
1 Year Performance	166.39%	130.64%	34.39%	27.68%

Taysha Gene Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSHA Taysha Gene Therapies	3.0648 of 5 stars	$6.34 +2.1%	$12.38 +95.3%	+166.4%	$1.82B	$9.77M	N/A	180	News Coverage Analyst Forecast High Trading Volume
HHH Howard Hughes	2.6835 of 5 stars	$66.81 -0.1%	$85.00 +27.2%	+6.6%	$3.99B	$1.51B	32.75	608	Positive News
PTGX Protagonist Therapeutics	0.9554 of 5 stars	$115.03 +1.9%	$115.21 +0.2%	+118.9%	$7.26B	$46.02M	N/A	120	News Coverage Analyst Downgrade Insider Trade
IMVT Immunovant	0.7441 of 5 stars	$38.10 +7.8%	$37.33 -2.0%	+141.3%	$7.26B	N/A	N/A	120	News Coverage Insider Trade
RYTM Rhythm Pharmaceuticals	2.7297 of 5 stars	$101.39 +4.8%	$133.13 +31.3%	+75.1%	$6.95B	$217.17M	N/A	140	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TSHA) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, PTGX, IMVT, RYTM, and LNTH

How does Taysha Gene Therapies compare to Howard Hughes?

Summary

How does Taysha Gene Therapies compare to Protagonist Therapeutics?

Summary

How does Taysha Gene Therapies compare to Immunovant?

Summary

How does Taysha Gene Therapies compare to Rhythm Pharmaceuticals?

Summary

How does Taysha Gene Therapies compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, PTGX, IMVT, RYTM, and LNTH

How does Taysha Gene Therapies compare to Howard Hughes?

Do analysts prefer HHH or TSHA?

Is HHH or TSHA more profitable?

Which has stronger earnings & valuation, HHH or TSHA?

Do insiders & institutionals hold more shares of HHH or TSHA?

Which has more risk & volatility, HHH or TSHA?

Does the media prefer HHH or TSHA?

Summary

How does Taysha Gene Therapies compare to Protagonist Therapeutics?

Is TSHA or PTGX more profitable?

Do institutionals & insiders have more ownership in TSHA or PTGX?

Which has stronger valuation and earnings, TSHA or PTGX?

Which has more risk and volatility, TSHA or PTGX?

Do analysts recommend TSHA or PTGX?

Does the media favor TSHA or PTGX?

Summary

How does Taysha Gene Therapies compare to Immunovant?

Do analysts rate IMVT or TSHA?

Which has more volatility & risk, IMVT or TSHA?

Do institutionals and insiders believe in IMVT or TSHA?

Does the media favor IMVT or TSHA?

Which has stronger earnings and valuation, IMVT or TSHA?

Is IMVT or TSHA more profitable?

Summary

How does Taysha Gene Therapies compare to Rhythm Pharmaceuticals?

Is TSHA or RYTM more profitable?

Do analysts recommend TSHA or RYTM?

Do institutionals & insiders have more ownership in TSHA or RYTM?

Which has higher valuation & earnings, TSHA or RYTM?

Does the media refer more to TSHA or RYTM?

Which has more risk & volatility, TSHA or RYTM?

Summary

How does Taysha Gene Therapies compare to Lantheus?

Is LNTH or TSHA more profitable?

Do analysts recommend LNTH or TSHA?

Do institutionals and insiders hold more shares of LNTH or TSHA?

Which has more volatility and risk, LNTH or TSHA?

Which has higher earnings & valuation, LNTH or TSHA?

Does the media favor LNTH or TSHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools